Drug intelligence / Profile preview

BGB-DXP604 + BGB-DXP593

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BGB-DXP604 + BGB-DXP593 is a combination of two monoclonal antibodies developed against SARS-CoV-2, intended for use in the prevention or treatment of COVID-19. Both are recombinant human monoclonal IgG antibodies that target the spike protein of SARS-CoV-2. The combination is designed to enhance neutralization breadth and reduce the risk of viral escape. The developer and main sponsor for clinical studies is BeiGene. Clinical evaluations have focused on safety, pharmacokinetics, immunogenicity, and overall tolerability in healthy participants, with endpoints including immunogenicity and PK when the agents are given alone or in combination[1][3][4].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on BGB-DXP604 + BGB-DXP593.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-DXP604 + BGB-DXP593.

Explore the full profile